Barbara Burtness, MD

Barbara Burtness, MD

Oncology New Haven, CT

Co-Leader Developmental Therapeutics

Office Address

  • 333 Cedar St
    New Haven, CT 06520
    Phone: (203) 737-7636

Barbara Burtness, MD

Oncology New Haven, CT

Co-Leader Developmental Therapeutics

Clinical Specialties & Interests

  • Oncology: General Oncology

Education & Medical Training

  • Bryn Mawr College
  • Memorial Sloan-Kettering
  • Stony Brook University School of MedicineStony Brook University School of Medicine
  • Yale-New Haven HospitalYale-New Haven Hospital

Certifications & Licensure

  • PA State Medical LicensePA State Medical License2005 - 2014
  • CT State Medical LicenseCT State Medical License1993 - 2015
  • American Board of Internal MedicineInternal Medicine, 1989
  • American Board of Internal MedicineMedical Oncology, 1993

Awards, Honors, & Recognition

  • Regional Top DoctorCastle Connolly, 2014

Clinical Trials

Publications & Presentations


Journal Articles

  • Images in Medicine: Cetuximab-associated acneiform rash.  Moss J and B Burtness, N Engl J Med 353:e17.
  • Oxaliplatin induces a delayed immune hemolytic anemia: A case report and review of the literature.  Noronha V, B Burtness, J Murren, TP Duffy., Clin Colorectal Ca 5:283-286
  • Bimodal population or pathologist artifact? Correspondence.  4. Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B, J Clin Oncol; 25:2487-8.

Books/Book Chapters

  • Novel targets in pancreatic cancer: focus on future paths to therapy.  
    Cohen S and B Burtness.
    Editors: .
  • Clinical use in colorectal cancer of monoclonal antibodies to the epidermal growth factor receptor.  
    Burtness B
    Editors: .
  • HER signaling in pancreatic cancer.  
    Burtness B
    Editors: .


  • EGFR inhibition in head and neck cancer – more insights but more questions Forastiere AA and BA Burtness., J Clin Oncol 25:2152-5
  • Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer. Shanbhag S and B Burtness, Eur J Clin Med Oncol
  • A 5 year follow up of an expanded phase II study evaluating adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high-risk breast cancer. Abu-Khalaf M, S Windsor, K Ebisu, S Salikooti, G Chung, M DiGiovanna, B Haffty, M Abrams, L Farber, AD Hsu, M Reiss, D Zelterman, B Burtness., Oncology 69:372-383.


  • Setting Up and Running Multicenter Randomized Trials. American Head and Neck Society Annual Meeting, Toronto.
  • Integrating Targeted Therapies into Standard Treatments, Meet the Professor Session. American Head and Neck Society Annual Meeting,Toronto.
  • Esophagogastric Discussion: Trials in Unselected Patients, Gastrointestinal (Non-colorectal) Oral Abstract Session. American Society of Clinical Oncology Annual Meeting, Chicago.

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • CIGNA Open Access
  • First Health PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
  • The full profile is locked and available to verified physicians only.
    Join over 50% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

Physicians, view Dr. Burtness's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV

© 2015 Doximity, Inc.HelpBlogCompanyContactPrivacyDirectory